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doi:10.1016/j.ejvs.2011.03.022Abstract Introduction: Evidence supports the introduction of an abdominal aortic aneurysm
(AAA) screening programme. The aims of this study were to estimate future disease patterns
and to determine the effect of the proportion attending on the programme’s cost-effective-
ness.
Patients and methods: The results of the local AAA screening programme were reviewed.
Ultrasonic infrarenal aortic diameter of 30 mm was considered aneurysmal. Projected popula-
tion numbers from the Department of Health and current disease prevalence were used to esti-
mate future number of potential patients. The Multi-centre Aneurysm Screening Study (MASS)
Markov model was used to calculate an incremental cost-effectiveness ratio (ICER) and 95%
uncertainty intervals (UI), using a 30-year time horizon and 3.5% per annum discount, to deter-
mine the effect of attendance.
Results: Men were recruited from August 2004 to May 2010. 13316 were invited for a scan and
5931 (44.5%) attended. 321 AAA were diagnosed, giving a prevalence of 5.4%, while 27 large
AAA (0.46%) were repaired. The annual incidence of AAA until 2021 will range from 441 to
526, with an incidence of 40e48 large AAA, with both showing a gradual increase with time.
Using this attendance rate, the ICER was calculated at £2350 per life-year gained (95% UI:
£1620e£4290), or £3020 per quality-adjusted life-year gained (95% UI: £2080e£5500).
Conclusions: The prevalence of disease in this local AAA screening was similar to other studies.
The low attendance will result in many AAA being missed, but will not impact greatly on the
long-term cost-effectiveness.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.8 90263494; fax: þ44 28 90263951.
internet.com (S.A. Badger).
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Abdominal aortic aneurysm (AAA) is a dilatation of the
aorta, with an estimated prevalence of 5% in males aged
between 65 and 79 years.1 The risk of mortality following
rupture is high and accounts for 2.1% of all deaths in men
aged 65 years and over in England and Wales.2 The number
of patients diagnosed in the United Kingdom with AAA, has
increased, with similar trends reported in other
countries.3e9 This is a real age-adjusted increase in inci-
dence, despite more elective AAA repairs being performed,
thus providing the impetus for AAA screening.3,4,6,10 The
concept of AAA screening fulfils all the relevant criteria as
stimulated by the United Kingdom National Screening
Committee and the World Health Organisation.11,12
The National Health Service (NHS) AAA Screening Pro-
gramme was introduced in England in March 2009 and has
cost £5,335,809 up to the end of March 2010.13 For the
programme to be considered ‘good value for money’ (i.e.
cost-effective) it must also be effective in reducing the
mortality and morbidity associated with AAA. However,
both the effectiveness, as measured by survival free from
mortality related to AAA within the timeframe, and cost-
effectiveness of a screening programme is dependent on
a number of variables, including a high attendance rate.14 A
number of randomised controlled trials have provided
evidence for screening effectiveness.15e18 Kim and
colleagues arguably provide the most robust evidence to
date that the cost-effectiveness of AAA screening improves
dramatically over time.15,19 They constructed a Markov
model with a 30-year (or until death) time horizon based on
the screening strategy and patient-level data from the
Multi-centre Aneurysm Screening Study (MASS). Both AAA
related and non-AAA mortality were incorporated into the
MASS model, using the UK national mortality statistics.
However, the MASS trial achieved a high attendance rate of
80%, which formed a key parameter in the model. This level
of uptake is in stark contrast to the 45% attendance
observed in Northern Ireland.20,21 This is disconcerting,
considering that the attendance rate in Northern Ireland
was also observed to vary with geographical location, with
a lower rate found in more socially deprived areas, where
prevalence of the disease is higher and a higher risk factor
profile is to be found.20
The national screening programme is envisaged to be
implemented in Northern Ireland by March 2011. Prior to
this it is imperative that the impact of low attendance on
the cost-effectiveness of the screening be established and
potential barriers to uptake be explored. A number of
limitations were outlined in the initial study, where a low
attendance rate (45%) among invited men was encoun-
tered, much lower than that acceptable for a national
screening programme.21 One significant disconcerting
feature to participants was that the screening programme
was being run as research and vulnerability to possible
unstated implications of research was confessed by many
non-attendees. Therefore, the local programme was for-
malised into an official hospital screening programme.
The cost-effectiveness of AAA screening has been shown
to be very favourable. The MASS results reported cost-
effectiveness at 4 years to be £28,400 per life-year gained,
equivalent to £36,000 per quality-adjusted life-year gained(QALY), thus on the borderline of acceptability, according
to current National Institute for Health and Clinical Excel-
lence (NICE) thresholds.22,23 Since costs are accrued in the
early years, the cost-effectiveness of AAA screening should
improve with time. Indeed it has been observed that the
actual 7 and 10 year cost-effectiveness calculations have
been reported, with the latter giving an incremental cost-
effectiveness ratio (ICER) of £7600 per life-year gained.24,25
Furthermore, when the results are extrapolated to 30
years, this falls further to £2320 per life-year gained.19
The aim of this study was, therefore, to investigate the
effect of the attendance at AAA screening on projected
future disease detection and management and the long-
term cost-effectiveness of such a programme.
Patients and Methods
Patient selection and screening
The methodology and patient selection of the Northern
Ireland screening study have been previously outlined in
detail.20,21 In summary General Practioners (GPs) were
asked to provide a list of males aged 65e75 years in their
practices. Patients who had previous AAA repair or already
diagnosed were excluded, as well as those who were
considered unsuitable for any surgical interventions, due to
medical co-morbidities.
All received a postal invitation to participate in the AAA
screening programme, accompanied with an information
sheet on the condition. After consent was obtained an
ultrasound scan of the abdominal aorta was performed. The
diagnostic threshold for AAA was 30 mm infrarenal diam-
eter. The patients were scanned in the supine position and
the aorta visualised longitudinally. If aneurysmal, the aorta
was measured transversely, with the maximum diameter
from outside wall to outside wall recorded. Subsequently,
appropriate follow-up or repair was arranged. Those who
had a normal (<30 mm) scan were discharged.
Projection of disease prevalence
As it was deemed to be service provision review, ethical
approval was not required. Population projections were
obtained from the Northern Ireland Statistics and Research
Agency website.26 The projected numbers of men aged 65
years each year until 2021 was obtained. Based upon the
calculated prevalence from the screening programme, the
total number of AAA in the present population was calcu-
lated. In addition, the projected number of aneurysms
likely to be detected by a national screening programme in
men at the age of 65 years was estimated.
Cost-effectiveness calculations
The Markov model based on the MASS trial was used to
investigate the potential impact of the lower attendance on
the 30-year cost-effectiveness of AAA screening. The full
details of the model’s structure, assumptions and parame-
ters are published elsewhere.22 In brief, men would be
invited for a one-off screen at 65 years, with no re-scre-
ening for negative results. After diagnosis, small AAA
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medium sized AAA three-monthly. When the AAA reached
55 mm referral for surgical consideration was made.
The time horizon was 30 years with the principal
outcomes being costs and life-years accrued with or
without screening. Both these parameters were dis-
counted at a rate of 3.5% per annum. Life-years were
adjusted for health-related quality of life using the age-
specific population norms for the EQ-5D to calculate
QALYs.27 The impact of uncertainty in the parameter
estimates used in the model on the cost-effectiveness of
screening was explored by simultaneously varying these
values according to their uncertainty distributions.15
Monte Carlo probabilistic sensitivity analysis (PSA) was
used to make 1000 independent draws of new parameter
values from each of the uncertainty distributions resulting
in different costs and effects for each strategy. Thus an
incremental cost-effectiveness (ICER) was calculated and
presented with 95% uncertainty intervals (UI) derived from
the PSA simulations.
Results
Patient recruitment
During the period August 2004 to July 2006 the screening was
performed as a research project. The data from August 2006
to May 2010, representing the official hospital screening
programme, was included for analysis. During the first phase
15 GP practices in Belfast, 1 in Saintfield and 7 in Lisburn
each supplied a list of men in the designated age group.
During the second phase, 112 GP practices in Belfast were
invited to supply patient details, but only 72 (64.3%) replied.
Attendance and disease prevalence
During the first phase of the screening programme, 3652
men were invited, of which 1659 (45.4%) attended for
a scan. A total of 92 (5.5%) were diagnosed with AAA, with
11 having a diameter greater than 55 mm, which is the
threshold for surgery. This was 12% of the AAA total and
0.7% of the screened cohort.Table 1 Projected total number of AAA in men in Northern Ire
Year All ages 65 years old
2008 869,817 8,211
2009 877,015 8,402
2010 883,838 8,159
2011 890,460 8,295
2012 896,824 8,858
2013 902,855 8,679
2014 908,857 8,663
2015 914,857 8,696
2016 920,817 8,769
2017 926,718 8,758
2018 932,514 9,030
2019 938,169 9,296
2020 943,644 9,435
2021 948,914 9,738During the second phase of the programme, 9664 were
invited, of which 4127 (42.7%) attended for scanning. A
total of 229 (5.5%) were diagnosed with AAA, with 16 having
a diameter greater than 55 mm. This was 7.0% of the AAA
total and 0.39% of the screened cohort.
Overall 13316 were invited, 5931 scanned. Attendance
was 44.5% and disease prevalence 5.4%, with the large AAA
constituting 8.4% of the AAA total, or 0.46% of the screened
cohort.
Projected aneurysm numbers
The present population size of Northern Irelandmen is shown
in Table 1, with the corresponding proportion aged 65 years.
Using the 5.4% overall AAA prevalence and 0.46% of large
AAA, the corresponding number of aneurysmswas calculated
for every year until 2021. Thesefigures do not take in account
any screening programme or repairs that may be performed
in the future. The annual incidence of new large AAA that
would be detected by a national screening programme was
calculated (Table 1). This does not account for the medium
sized aneurysms that would grow after detection to a size
that would require surgical repair.
The low attendance rates encountered in this study will
have a detrimental effect on the screening programme. The
impact of the low attendance on the number of large AAA
missed that would not be diagnosed, with potential to
rupture are outlined in Table 2. The effect of the attendance
rates on the pickup of small AAA,whichmay continue to grow
towards the surgical threshold, is shown in Table 3.
Cost-effectiveness
The Markov model based on the MASS trial was used to
investigate the potential impact of the lower attendance
observed in Northern Ireland (44.5%) on the 30-year cost-
effectiveness of AAA screening. All other modelling
assumptions and parameters were retained form the orig-
inal MASS based model. This was found to be £2350 per life-
year gained (95% UI: £1620e£4290), where the incremental
costs are £33.22 and the life-years gained are 0.0141 years.
After adjusting life-years for age-specific health-relatedland.
AAA at 5.4% Large AAA at 0.46%
443 40
454 41
441 40
448 41
478 43
469 43
468 42
469 43
474 43
473 43
488 44
502 46
509 46
526 48
Table 2 Projected number of AAA detected according to
attendance rates.
Year 100% 80% 60% 50% 40%
2008 443 355 266 222 177
2009 454 363 272 227 181
2010 441 353 264 220 176
2011 448 358 269 224 179
2012 478 383 287 239 191
2013 469 375 281 234 187
2014 468 374 281 234 187
2015 469 376 281 235 188
2016 474 379 294 237 189
2017 473 378 284 236 189
2018 488 390 292 244 195
2019 502 402 301 251 201
2020 509 408 306 255 204
2021 526 421 316 263 210
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gained (95% UI: £2080e£5500), where the incremental costs
were £33.22 and QALYs gained were 0.0110.
Discussion
Clear evidence has been provided by four randomised
controlled trials for AAA screening to be implemented.15e18
In Northern Ireland, the success of such screening has been
assessed by research with surprising results.20,21 Although
the increase in prevalence in high-risk patients was
expected, the lack of influence of a family history was not.
In addition, while prevalence was similar to the rest of the
literature, the initial study demonstrated a distinct
problem of attendance, with only approximately 45% of
men willing to attend. Attendance, like prevalence, varied
with the degree of social deprivation, but maximal atten-
dance only reached 55%.20 This present study provided an
opportunity to discover if attendance was influenced by the
description in patient related literature that the screening
programme was research. There was in fact a decrease inTable 3 Projected number of large AAA detected
according to attendance rates.
Year 100% 80% 60% 50% 40%
2008 40 32 24 20 16
2009 41 33 25 21 16
2010 40 32 24 20 16
2011 41 33 24 20 16
2012 43 35 26 22 17
2013 43 34 26 21 17
2014 42 34 25 21 17
2015 43 34 26 21 17
2016 43 34 26 21 17
2017 43 34 26 21 17
2018 44 35 27 22 17
2019 46 36 27 23 18
2020 46 37 28 23 18
2021 48 38 29 24 19attendance, indicating that the reason for failure to come
may have been either a deep-seated apathy towards
preventative medicine or an ignorance of both the disease
and its potential lethal outcome. This was even after the
patient information sheet had been provided. In addition,
a fear of being given bad news in a new diagnosis, may have
contributed towards their rationale and this lack of atten-
dance has similarly been seen in other screening programmes
in Northern Ireland, such as breast and cervical cancer.28
Another problem encountered in the study was a lack of
willing input from primary care physicians. While we were
very thankful for the help that was provided, and
acknowledge their busy schedule, it proved surprising how
some doctors were slow to respond, rather than seizing this
as an opportunity to enhance the health care provision.
However, this pilot study has highlighted areas where closer
co-operation and alternative organisation could provide
and better future service. This was interlinked with another
problem, in that screening participants expressed a desire
to attend for a scan in a more convenient location, such as
their GP’s health centre. The centralised location, although
convenient for the screeners, was more daunting for
participants, particularly if they felt well and had no loyalty
or affiliation with the hospital, unlike their GP.
The low attendance will pose a significant problem for
the official AAA screening programme and must be urgently
addressed, otherwise it will negate some of the benefit that
it is designed to provide in ruptured AAA prevention. A high
level of attendance is required to make the programme
effective. The advantage of decreasing the rate of death
from ruptured AAA will be lost, even after the ten years
required to notice this. There will therefore, be an increase
in elective follow-up of small AAA and elective surgery for
the large AAA, with possibly no meaningful compensatory
decrease in rupture presentation, surgery and the high-cost
post-operative care and follow-up.
The present study has some weaknesses. The use of
prevalence in the group aged 65e75 years to calculate future
incidence is likely to overestimate patient numbers. The
other factor that could exacerbate this problem is the recent
suggestions that AAA disease is declining in prevalence. In
addition, the projection of data based upon 45% of the
populationmay result in inaccuracies, as this proportionmay
not reflect the overall population disease patterns.
The MASS trial provided evidence in support of the cost-
effectiveness of AAA screening. This is not without contro-
versy, as other large studies conclude otherwise.29 It is also
dependent on the selection of an appropriate target pop-
ulation, clinical setting and with a long-term perspective, but
attendance rates may not be as crucial as expected.30e32
However a recent meta-analysis of 8 cost-effectiveness
studies concluded that it would probably gain additional life
years and quality of life at acceptable extra costs.33 The
majority of studies have concentrated on the short-termcost-
effectiveness of AAA screening. They are also weakened by
a number of optimistic assumptions, which have been avoided
in the use of the presentmodel.15,34While the lowattendance
in Northern Ireland is concerning, it is encouraging that the
long-term cost-effectiveness of AAA screening is highly
attractive. The ICERs are comparable with the MASS trial,
which had 80% attendance. The highly favourable results are
due to the low attendance leading to substantially reduced
438 S.A. Badger et al.costs in the screening arm and hence reduced incremental
costs, in addition to a reduction of the life-years gained.
Although the results of this study are particularly impor-
tant in the local context, they are likely to reflect potential
problems elsewhere in the UK. Therefore, on reflection of
these data, the present authors would put forth some
recommendations, so that the national AAA screening pro-
gramme success is not jeopardised. Firstly, a greater effort
must be made by all medical personnel, in both primary and
secondary health care to promote prophylactic health
measures, such as AAA screening. This is particularly perti-
nent for theGP,whonaturally has a better rapportwith these
men. Secondly, disease education will prove crucial. This
could be achieved as advertisements in local and national
media, as well as direct mailing of the target individuals.
Thirdly, the screening andeducation could be integrated into
the context of general health promotion and detection and in
particular as part of an overall cardiovascular health
promotion service. This holistic approach would achieve
much more, since the modification of similar risk factors
would treat several disease processes concurrently.
Fourthly, the location of the Northern Ireland and national
AAA screening service needs careful consideration. While
central coordination is essential, men are reluctant to travel
long distance for screening, as demonstrated before and in
this study.20 This couldbeachievedbyeither amobile unit, or
the utilisation of local health centres.
Future research should concentrate on the reasons for
non-attendance and to assess if the recommendations
above are accurate and effective. Qualitative research,
through questionnaires and focus groups may help to
elucidate the rationale behind a lack of attendance that
makes it stand in marked contrast to other AAA screening
programmes. A similar approach with GPs would highlight
their concerns and ensure fuller co-operation, as the
success of the national programme requires complete
participation of the multidisciplinary team.
In conclusion, AAA screening has proven its importance
by detection of undiagnosed disease. However, the low
rates of attendance consistently encountered over the past
4 years, may endanger the overall success of the screening
programme, but it will remain cost-effective.
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